Please find attached herewith intimation regarding change in directors of the Company
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies Board approved multiple items at its May 7, 2026 meeting. Key decisions include recommending a final dividend of Rs. 7 per share (total FY26 dividend of Rs. 9.33 per share post bonus adjustment), appointing Price Waterhouse Chartered Accountants LLP as new statutory auditors for a 5-year term replacing M S K A & Associates, and re-appointing CEO Rahul Franklin Guha for another 5 years (May 2027 to May 2032). The Board also appointed two new Non-Executive Non-Independent Directors - Mr. Uday Patel Kadam and Mr. Gaurav Verma (both effective May 8, 2026) from API Holdings. Concurrently, two Non-Executive Non-Independent Directors - Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah - resigned effective May 7, 2026 citing pre-occupation. Additionally, the Board approved investment of up to Rs. 5.5 crore in Think Health Diagnostics Private Limited (wholly owned subsidiary) and proposed amendments to the Memorandum of Association to align with Companies Act 2013 and expand business scope.
The resignation of two directors and simultaneous appointment of two new directors from API Holdings indicates significant board changes. The CFO was not mentioned. Investors should note the related party transaction for Think Health investment and the upcoming auditor change. The MOA expansion signals potential diversification into broader healthcare and diagnostics activities.